Medtronic Yields More, Abbott Diversifies Better

Medtronic presents the more attractive immediate income proposition, yielding 3.11% on a forward annualized payout of $2.88. This exceeds Abbott Laboratories' 2.4% yield on $2.52, despite Medtronic trading at a lower forward P/E of 15 compared to Abbott's 17. The valuation gap suggests Medtronic is currently priced for value, while Abbott commands a premium for its broader business mix.

However, the long-term compounding profile favors Abbott, which delivered a 203% return over the past decade against Medtronic's 40%. Abbott has maintained a 54-year streak of dividend increases, outpacing Medtronic's 49-year record. Recent payout adjustments reflect this momentum, with Abbott raising its quarterly dividend from $0.59 to $0.63, while Medtronic moved from $0.71 to $0.72.

Abbott Broadens Franchise Via Acquisition

Abbott’s business model is significantly more diversified, spanning medical devices, diagnostics, pharmaceuticals, and nutrition. The completion of the $21 billion Exact Sciences acquisition in March 2026 further strengthened its diagnostics segment. This diversification acts as a buffer against reimbursement shocks or regulatory changes that could disproportionately impact a single-segment player like Medtronic.

Financial performance in Q2 2026 underscored this breadth, with Abbott reporting revenue of $12.59 billion, a 13.02% year-over-year increase. Medical devices contributed 9.0% to this growth, while continuous glucose monitors surpassed $2 billion in quarterly sales. Abbott also returned $2.1 billion to shareholders in this quarter alone through dividends and share buybacks.

Medtronic Cash Flow Supports Payouts

Medtronic’s dividend sustainability is backed by robust cash generation, having produced $7.33 billion in operating cash flow in FY26 against a $3.64 billion dividend payout. This coverage ratio provides a solid foundation for maintaining its 49-year dividend growth streak. The company’s focus remains on delivering higher immediate income per dollar invested compared to its peer.

Guidance Risks Affect Valuation

The critical risk for Medtronic investors is its recent performance trajectory. The company has beaten EPS estimates for five consecutive quarters, setting a high bar for future guidance. A potential miss in fiscal year 2027 could erode the valuation advantage that currently supports its higher yield. Conversely, Abbott’s diversified revenue streams mitigate the impact of any single product line underperforming relative to expectations.